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Background: Resistin is an adipocytokine that may link insulin resistance, inflammation and atherosclerosis. Resistin up-regulates the expression 
of adhesion molecules in endothelial cells and promotes smooth muscle cell proliferation. Serum resistin levels were reported to be high in patients 
(pts) with coronary artery disease, especially unstable angina (UA).
Method: We investigated prognostic value of pre-procedural serum resistin levels by ELISA on clinical outcome and restenosis in 140 pts 
undergoing percutaneous coronary intervention (PCI), of whom 97 (69%) had bare metal stent. AMI pts were excluded. Restenosis was defined as 
>50% diameter stenosis at follow-up angiography. Pts were followed up for 3 years for major adverse cardiovascular events (MACE) (death, MI, UA, 
stroke).
Results: At 8±6 months after PCI, re-angiography was performed in 94 (67%) pts, of whom 42 had restenosis. Between 42 pts with restenosis and 
52 without it, serum resistin (median 3.9 vs 3.5 ng/ml) and C-reactive protein (CRP) (0.70 vs 0.70 mg/l) levels did not differ (P=NS). In multivariate 
analysis, resistin or CRP levels were not independent predictors for restenosis. During the 3-year follow-up, MACE occurred in 24 pts (1 death, 21 
UA and 2 stroke). Compared with 116 pts without MACE, 24 with MACE had higher resistin (5.0 vs 3.5 ng/ml, P<0.01) and CRP (1.30 vs 0.60 mg/l, 
P<0.01) levels. Pts with MACE more often had resistin level of >4.0 ng/ml than pts without MACE (75% vs 35%, P<0.001). However, resistin levels 
correlated with CRP levels (r=0.31) but not with HOMA-IR or insulin levels. To clarify the association between MACE and resistin, 140 pts were 
divided into 2 groups by resistin levels. Kaplan-Meier analysis showed a lower event-free survival rate in pts with resistin level >4.0 ng/ml than pts 
without it (P<0.001). In multivariate analysis, resistin levels were found to be a predictor for MACE independent of risk factors and CRP. Hazard ratios 
for MACE were 3.6 (95%CI=1.4-9.2, P<0.01) for resistin >4.0 ng/ml.
Conclusion: Resistin may be related to inflammation. However, serum resistin levels were found to be a predictor for cardiovascular events, but 
not for restenosis, in pts undergoing PCI independent of CRP levels.
